Method of treating a synthetic or naturally occuring surface with microvascular endothelial cells, and the treated surface itself

• US 4,820,626 A
• Filed: 06/06/1985
• Issued: 04/11/1989
• Est. Priority Date: 06/06/1985
• Status: Expired due to Term

• Current Assignee: Thomas Jefferson University 11TH and Walnut Streets Philadelphia PA 19107
• Original Assignee: Thomas Jefferson University (Main Line Health System)
• Inventors: Williams, Stuart K., Jarrell, Bruce E.
• Primary Examiner(s): Tarcza, John E.
• Application Number:
  US06/742,086
• Time in Patent Office: 1,405 Days
• Field of Search: 435/240, 424/93, 623/1
• US Class Current: 435/1.1
• CPC Class Codes: A61L 27/34 Macromolecular materials
• CPC Class Codes: A61L 27/507 for artificial blood vessels apparatus for applying cells on a blood vessel prosthesis A61F2/062
• CPC Class Codes: C08L 89/06 derived from leather or skin , e.g. gelatin

Abstract

The present invention provides a novel method of treating a synthetic or naturally occurring implant, such as a vascular graft, intended for implantation in a human patient, comprising obtaining human microvascular rich tissue from that patient; separating microvascular endothelial cells from that tissue; and placing said microvascular endothelial cells onto said implant to provide at least about 50% confluence of said cells on the surface of said implant to be treated. In the preferred embodiment, the microvascular rich tissue is perinephric fat, which is obtained from the donor and subjected to a digestive separation process to provide an abundant supply of microvascular endothelial cells. In the preferred embodiment, these microvascular endothelial cells are placed onto the implant by suspending them in a protein (plasma) containing physiologic saline solution, which is incubated on the graft until the endothelial cells either adhere to the graft surface or clot within the protein solution. An efficient method is therefore provided which will permit a patient to donate excess microvascularized tissue which may be used to procure autologous endothelial cells which are subsequently used to treat a graft or other implant to provide at least 50% confluence while his related surgical procedure is in progress.

Claims

1. A method of treating an implant intended for implantation in a human patient, comprising:

obtaining human microvascular rich tissue from that patient;

separating microvascular endothelial cells from said patient'"'"'s tissue;

applying said separated uncultured microvascular endothelial cells onto said implant to provide at least about 50% confluence of said cells on the surface of said implant to be treated; and

implanting said implant into a patient without culturing.

2. The method of claim 1 wherein said tissue is fat tissue.

3. The method of claim 2 wherein said fat tissue is perinephric fat.

4. The method of claim 2 wherein said fat tissue is subcutaneous fat.

5. The method of claim 1 wherein said tissue is omentum.

6. The method of claim 1 wherein said tissue is intrathoracic.

7. The method of claim 1 wherein said tissue is intraperitoneal.

8. The method of claim 1 wherein said method further comprises implanting said implant to said donor.

9. The method of claim 8 wherein said method is performed in its entirety in a single sterile environment.

10. The method of claim 1 wherein said implant is a vascular graft.

11. The method of claim 10 wherein said vascular graft is a polyester graft.

12. The method of claim 1 wherein said separating step is conducted using a proteolytic enzyme.

13. The method of claim 12 wherein said proteolytic enzyme is a collagenase.

14. The method of claim 13 wherein said proteolytic enzyme comprises caseanase and trypsin.

15. The method of claim 12 wherein said separating step comprises incubating said tissue with said proteolytic enzyme until this tissue mass disperses to produce a tissue digest.

16. The method of claim 13 wherein microvascular endothelial cells are separated from said digest.

17. The method of claim 16 wherein said microvascular endothelial cells are separated by low speed centrifugation to produce an endothelial cell rich pellet.

18. The method of claim 17 wherein said pellet is washed with a buffered saline solution.

19. The method of claim 16 wherein said endothelial cells are purified from said pellet by centrifugation in a continuous gradient and harvesting of the endothelial cell band or by selective sieving of endothelial cells.

20. The method of claim 1 wherein said applying step comprises suspending said microvascular endothelial cells in a buffered saline solution.

21. The method of claim 20 wherein said suspending step comprises suspending in a buffered saline solution comprising about 1% protein.

22. The method of claim 20 wherein said separating step comprises obtaining a microvascular endothelial cell rich pellet, and wherein said suspending step comprises suspending said pellets in said buffered saline solution in a pellet to solution volumetric ratio of 1:

5 to 1;

15.

23. The method of claim 22 wherein said ratio is about 1:

10.

24. The method of claim 1 wherein said microvascular endothelial cells are applied in suspension in a physiologic solution, to the surface of the implant to be treated.

25. The method of claim 24 wherein said surface of said implant is pretreated with protein.

26. The method of claim 25 wherein said protein is plasma protein.

27. The method of claim 26 wherein said plasma protein is said human patient'"'"'s plasma.

28. The method of claim 26 wherein said protein pretreatment comprises applying platelet rich plasma or blood to said surface of said implant.

29. The method of claim 24 wherein said microvascular endothelial cells are incubated on said surface until adherence to provide at least 50% confluence occurs.

30. The method of claim 29 wherein said application provides confluent or near confluent endothelial cell coverage.

31. The method of claim 24 wherein said microvascular endothelial cells are provided at a rate in excess of 100% confluence.

32. The method of claim 24 wherein said surface of said implant has been pretreated to emulate a protein surface.

33. The method of claim 24 wherein said microvascular endothelial cells are preclotted in a protein gel applied to said graft.

34. The method of claim 33 wherein said protein gel is a fibrin gel.

35. The method of claim 33 herein said microvascular endothelial cells are preclotted in human plasma.

36. The method of claim 35 wherein said plasma is said patient'"'"'s plasma.

37. The method of claim 1 wherein said implant is selected to be a vascular graft.

38. The method of claim 37 wherein said graft is a polyester graft.